Media Release: Cannatrek Signs Landmark Deal With iX Biopharma’s Subsidiary To Distribute Medicinal Cannabis Via Novel Sublingual Wafer


Posted on April 29th, by Bourse Communications in News and Announcements. Comments Off on Media Release: Cannatrek Signs Landmark Deal With iX Biopharma’s Subsidiary To Distribute Medicinal Cannabis Via Novel Sublingual Wafer

Australian seed-to-patient medicinal cannabis producer Cannatrek Ltd (“Cannatrek”) announced today it has signed an agreement with iX Syrinx Pty Ltd, a wholly owned subsidiary of Singapore-listed specialty pharmaceutical company iX Biopharma, to distribute sublingual (under the tongue) medicinal cannabis wafers in Australia.

The wafers are formulated with iX Biopharma’s patented sublingual delivery technology, WaferiX®. The WaferiX® delivery overcomes three common problems with the delivery of medicinal cannabis – lack of fixed unit dosages, inconsistent absorption and variable or poor bioavailability.

In commenting on the deal, Tommy Huppert, CEO of Cannatrek, said:

“The supply agreement with iX Syrinx Pty Ltd was a natural progression of Cannatrek’s seed-to-patient growth plans, which includes the development of different cannabinoid formulations into active ingredients to treat different diseases and their symptoms like insomnia, pain and stress.

“We are committed to providing patients with safe, affordable and effective treatments. Built upon the novel and patented WaferiX® technology, the unique and superior sublingual cannabis wafers are well-positioned to disrupt the current market of medicinal cannabis products.”

Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said:

“We are excited to partner with leaders like Cannatrek to reach Australian patients through their well-established network of prescribers and pharmacies. Patients are now more knowledgeable about the advantages of sublingually administered cannabis medicines in increasing bioavailability and improving patient outcomes. We are confident that our sublingual technology, which is clinically proven and widely used across our pharmaceutical and nutraceutical product portfolio, will allow us to better serve patient need and expectation.”

Cannatrek is currently harvesting medicinal cannabis under government permits at its Brisbane facility and will shortly begin building over phases one of the world’s largest medicinal cannabis operations in the central Victorian city of Shepparton. The 160,000 square-metre facility in Shepparton will produce 160 tonnes of medicinal cannabis a year once fully constructed for the Australian pharmaceutical industry, which currently has no local supplier at scale. The Shepparton facility will eventually require more than 400 jobs a year in regional Victoria, with many more during the building process.

The legalisation and widespread use of cannabis and cannabinoids for medicinal purposes is happening at an unprecedented pace worldwide. Mr Huppert said, ’CBD in particular, one of the primary non-intoxicating compounds found in the cannabis plant, has attracted growing interest due to its safety and efficacy in treating many health conditions, including chronic pain, anxiety, movement and sleep disorders.’

The Australian cannabis market is expected to grow from an estimated US$0.04 billion in 2020 to US$1.23 billion by 2024. 1

1 Prohibition Partners, 2020, “The Oceania Cannabis Report, Second Edition, April 2020”  

About Cannatrek Ltd

Cannatrek is a fully licensed medicinal cannabis enterprise in Australia, operating as a first mover in the nascent medical cannabis industry, with licences in hand to operate from seed to patient. Cannatrek is developing complete vertical integration, from biomedical research and education, cultivation and green technology, through to processing and smart packaging, as well as a secure blockchain to cover end-to-end distribution. Cannatrek was recently awarded Major Project Status from the Federal Government for its $160 million production facility in the Victorian regional city of Shepparton. When operating at full production, Cannatrek aims to produce 160 tonnes of medicinal cannabis per year, which will make it one of the world’s largest medicinal cannabis facilities. Cannatrek also has an extensive global wholesale and national distribution network in Australia.

cannatrek.com.au

About iX Biopharma

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

Apart from the sublingual medicinal cannabis wafer, iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. 

ixbiopharma.com

For further information please contact:
Rod North
, Managing Director,
Bourse Communications Pty Ltd
T:
 (03) 9510 8309, M: 0408 670 706,
E: [email protected]





Comments are closed.